Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
45
pubmed:dateCreated
2008-11-13
pubmed:abstractText
NK cells are promising effectors for tumor adoptive immunotherapy, particularly when considering the targeting of MHC class I low or negative tumors. Yet, NK cells cannot respond to many tumors, which is particularly the case for nonhematopoietic tumors such as carcinomas or melanoma even when these cells lose MHC class I surface expression. Therefore, we targeted primary human NK cells by gene transfer of an activating chimeric receptor specific for HER-2, which is frequently overexpressed on carcinomas. We found that these targeted NK cells were specifically activated upon recognition of all evaluated HER-2 positive tumor cells, including autologous targets, as indicated by high levels of cytokine secretion as well as degranulation. The magnitude of this specific response correlated with the level of HER-2 expression on the tumor cells. Finally, these receptor transduced NK cells, but not their mock transduced counterpart, efficiently eradicated tumor cells in RAG2 knockout mice as visualized by in vivo imaging. Taken together, these results indicate that the expression of this activating receptor overrides inhibitory signals in primary human NK cells and directs them specifically toward HER-2 expressing tumor cells both in vitro and in vivo.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-10510357, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-10570277, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-10626898, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-10658975, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-11248153, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-11342440, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-11557981, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-11562472, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-11592078, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-12102744, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-12149207, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-12412486, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-12960359, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-14528282, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-14618618, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-15214036, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-15338747, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-15585893, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-15632206, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-15753400, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-15755898, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-15771571, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-15868915, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-16740393, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-16782917, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-16827104, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-16914327, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-16935000, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-17085641, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-17100871, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-17100877, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-17100882, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-17100883, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-17100886, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-17157791, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-18354418, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-2470152, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-2683611, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-2960890, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-3951539, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-8537970, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-9368779, http://linkedlifedata.com/resource/pubmed/commentcorrection/18987320-9371813
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1091-6490
pubmed:author
pubmed:issnType
Electronic
pubmed:day
11
pubmed:volume
105
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
17481-6
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas.
pubmed:affiliation
Max-Delbrück Center for Molecular Medicine, D-13092 Berlin, Germany.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't